-
Genfit S.A. (Euronext:ALGFT) gained EUR 1.57 (84%) to EUR 3.45 on Friday after GFT505 met the co-primary endpoints of improving insulin sensitivity in the liver and peripheral tissues in the Phase II GFT505-210-6 trial …
Published on 2/3/2012
-
AB Science S.A. (Euronext:AB) jumped EUR 4.42 (72%) to EUR 10.60 on Thursday after releasing data late Wednesday from a Phase II trial of masitinib to treat gastrointestinal stromal tumors (GIST). Second-line treatment …
Published on 2/2/2012
-
Astellas Pharma Inc. (Tokyo:4503) said oral JAK inhibitor ASP015K met the primary endpoint of significantly improving Psoriasis Area and Severity Index (PASI) score from baseline to day 42 vs. placebo in a Phase IIa …
Published on 2/2/2012
-
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) said a greater proportion of patients receiving OGX-427 plus prednisone were progression free at 12 weeks, the primary endpoint, vs. prednisone alone in a Phase II trial to …
Published on 2/2/2012
-
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) gained $1 (23%) to $5.39 on Thursday after it and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said lubiprostone met the primary endpoint in a Phase III trial to treat …
Published on 2/2/2012
-
AB Science S.A. (Euronext:AB) said second-line treatment with masitinib significantly improved median overall survival (OS), a secondary endpoint, vs. Sutent sunitinib at a median follow-up of 14 months in a Phase II …
Published on 2/1/2012
-
Medivation Inc. (NASDAQ:MDVN) and partner Astellas Pharma Inc. (Tokyo:4503) said once-daily oral MDV3100 met the secondary endpoints of radiographic and prostate specific antigen (PSA) response rates and time to disease…
Published on 1/31/2012
-
BTG plc (LSE:BGC) said Varisolve met the primary endpoint in the U.S. Phase III VANISH-2 trial to treat varicose veins. In 235 patients with symptomatic and visible varicose veins and saphenofemoral junction …
Published on 1/30/2012
-
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) fell $3.97 (40%) to $5.98 on Friday after an interim analysis showed saridegib plus gemcitabine would not meet the primary endpoint of median overall survival vs. gemcitabine …
Published on 1/27/2012
-
Lpath Inc. (OTCBB:LPTN) suspended dosing of ophthalmic product iSONEP in two trials because the company's fill/finish contractor, Formatech Inc. (Andover, Mass.), did not meet cGMP requirements. Lpath said the move is …
Published on 1/27/2012
-
Advanced Cell Technology Inc. (OTCBB:ACTC) said the sub-retinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in two patients with ophthalmic disease showed no adverse …
Published on 1/23/2012
-
EMA's CHMP adopted a final qualification opinion that low hippocampal volume is predictive of Alzheimer's disease-type dementia in patients with cognitive impairment. The MRI-detected biomarker can now be used in …
Published on 1/23/2012
-
EMA's CHMP released draft guidance on the development of biosimilar versions of multiple sclerosis (MS) drug interferon beta. The draft outlines non-clinical and clinical requirements, including comparative in vitro …
Published on 1/19/2012
-
Bayer AG (Xetra:BAYN) and partner Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) reported additional data from the Phase III CORRECT trial in 760 metastatic colorectal cancer (mCRC) patients who have progressed after standard …
Published on 1/18/2012
-
ArQule Inc. (NASDAQ:ARQL) gained $0.71 (12%) to $6.67 on Tuesday after oral tivantinib met the primary endpoint of significantly improving time to progression vs. placebo in a Phase II trial to treat unresectable …
Published on 1/17/2012
-
Medivation Inc. (NASDAQ:MDVN) and Pfizer Inc. (NYSE:PFE) discontinued development of Dimebon latrepirdine for all indications and terminated a 2008 deal after reporting data from the Phase III CONCERT trial to treat …
Published on 1/17/2012
-
FDA's Arthritis Advisory Committee will meet on March 12 to discuss safety issues possibly related to anti-nerve growth factor (NGF) compounds. The agency will ask the committee to determine whether reports of joint …
Published on 1/10/2012
-
Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said itolizumab met the primary endpoint of a significantly greater proportion of patients achieving a PASI 75 response at week 12 vs. placebo in the Phase III TREAT-PLAQ trial to …
Published on 1/9/2012
-
Theravance Inc. (NASDAQ:THRX) fell $3.81 (19%) to $16.39 on Monday after it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) released top-line data from nine trials of Relovair fluticasone furoate/vilanterol to treat…
Published on 1/9/2012
-
Durect Corp. (NASDAQ:DRRX) fell $0.44 (38%) to $0.74 on Friday after reporting top-line data from the Phase III BESST trial of Posidur to treat post-operative pain. In patients undergoing laparoscopically assisted …
Published on 1/6/2012
-
ProFibrix B.V. (Leiden, the Netherlands) said topical Fibrocaps followed by the Gelfoam absorbable gelatin sponge met the primary endpoint of reducing mean time to hemostasis vs. Gelfoam alone in a U.S. Phase II trial …
Published on 1/5/2012
-
Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $3.37 (20%) to $13.83 on Tuesday despite reporting that oral tivozanib met the primary endpoint of median progression-free survival (PFS) vs. sorafenib in the Phase III TIVO-…
Published on 1/3/2012
-
Osiris Therapeutics Inc. (NASDAQ:OSIR) fell $0.18 to $5.17 on Tuesday after reporting that there was no significant difference between Prochymal and placebo in the rate of disease progression as measured by stimulated C…
Published on 1/3/2012
-
The Scripps Research Institute named Michael Marletta president and CEO. Marletta, who joined the Scripps faculty in July 2011, was formerly a professor of biochemistry and chair of the Department of Chemistry at the …
Published on 1/3/2012
-
Avastin bevacizumab missed the secondary endpoint of overall survival in the Phase III GOG-0218 trial in patients with previously untreated advanced ovarian cancer, according to data published Thursday in the New …
Published on 12/29/2011